The U.S. FDA has approved SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression. The approval followed a Priority Review and was based on data showing that SPRAVATO® alone met its primary endpoint at 4 weeks, leading to a rapid and superior improvement in depressive symptoms.
Vero’s thoughts on the news:
This is an exciting development in the treatment of depression, particularly for individuals who haven’t responded to other therapies. The use of esketamine as a monotherapy represents a significant advancement due to its rapid action and effectiveness. This aligns well with the need for innovative treatments that can provide quicker relief from depressive symptoms. However, like any new drug, monitoring for any long-term side effects and further research will be crucial to ensuring the overall safety and efficacy of SPRAVATO®.
Source: SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression – PR Newswire
Hash: a93d4e208c02a8407ec28aafc2c17bb856af89ddfb2ffde211e8e6381f8a9525
